|Calculated MW||134277 Da|
|Purification||Antisera to human EGF R were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography.|
|Immunogen||Synthetic Peptide corresponding to the C-Terminal domain of Human EGF R, conjugated to Keyhole Limpet Hemocyanin (KLH).|
|Shelf Life||18 months from date of despatch.|
|Other Names||Epidermal growth factor receptor, 18.104.22.168, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1|
|Target/Specificity||ABD11019 recognises an epitope on the C-Terminal domain of Human Epidermal Growth Factor Receptor (EGFR, EGR-R), a 175 kDa transmembrane glycoprotein belonging to the ErbB receptor tyrosine kinase family. EGFR is the cell surface receptor for members of the EGF family, and functions in early embryonic development and in the renewal of stem cells in tissues such as the skin, liver and gut.EGFR is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas, high level expression of EGFR is often associated with advanced disease and poor prognosis.Mutations to EGFR have been found in many human carcinomas including breast, brain, lung, and colon. Over-expression of more than one member of the ErbB family was found to have a negative synergistic effect on patient outcome.|
|Preservative & Stabilisers||0.1% Sodium Azide (NaN3)|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human EGF Receptor (C-Terminal) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Moura, V. et al. (2012) Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.Breast Cancer Res Treat. 133: 61-73.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.